FDA & Government News

FDA Approves GSK’s 5-in-1 MenABCWY Vaccine

FDA approves GSK’s Penmenvy, a 5-in-1 meningococcal vaccine for adolescents and young adults, targeting five major serogroups of Neisseria meningitidis that cause invasive meningococcal disease.

Share

The U.S. FDA approved the meningococcal groups A, B, C, W, and Y vaccine (Penmenvy) for patients aged 10 to 25 years. This pentavalent vaccine targets the major serogroups of Neisseria meningitidis responsible for invasive meningococcal disease (IMD). Data from phase III trials supported the approval and demonstrated a safety profile consistent with existing GSK meningococcal vaccines. The vaccine combines components from other vaccines, reducing the number of required injections. The approval aims to improve vaccination coverage, especially for IMD caused by serogroup B. The U.S. CDC's Advisory Committee on Immunization Practices is scheduled to vote on recommendations for the vaccine's use in adolescents and young adults in February 2025.

Original Source(s)

FDA Approves GSK’s 5-in-1 MenABCWY Vaccine

FDA approves GSK’s Penmenvy, a 5-in-1 meningococcal vaccine for adolescents and young adults, targeting five major serogroups of Neisseria meningitidis that cause invasive meningococcal disease.

  • by Kathryn Wighton

  • February 17, 2025

  • 2 min

Related Content

Are Antibiotics Needed for Pediatric Pneumonia?

Study: U.S. Child Allergy Rates Shifted During Pandemic

How Does Trisomy 21 Affect Fetal Hematopoiesis?

Fetal hematopoietic stem cells in Down syndrome are 'primed' for differentiation, as revealed by single-cell multi-omics of over 1.1 million cells, potentially explaining early hematological abnormalities.